Join the Nirsevimab group to help and get support from people like you.
Nirsevimab News
Nirsevimab Effective for Preventing RSV-Linked Hospitalization
FRIDAY, March 8, 2024 – Receipt of a single dose of nirsevimab is effective for preventing respiratory syncytial virus (RSV)-associated hospitalization for infants, according to research published...
Nirsevimab Protects Infants Against RSV-Linked Hospitalization
THURSDAY, Dec. 28, 2023 – Nirsevimab is efficacious for preventing hospitalization for respiratory syncytial virus (RSV)-associated lower respiratory tract infection among infants, according to a...
Shortage of Shots That Protect Babies Against RSV Prompts CDC Alert
TUESDAY, Oct. 24, 2023 – Demand for a new shot that protects babies against respiratory syncytial virus (RSV) has outpaced supply, prompting U.S. health officials to recommend the doses be saved for...
Pediatricians' Group Urges That All Infants Get New RSV Shot
WEDNESDAY, Aug. 16, 2023 – All infants should receive the new long-acting preventive monoclonal antibody for respiratory syncytial virus (RSV), the nation's leading pediatrics group said. The...
Pediatricians' Group Urges That All Infants Get New RSV Shot
WEDNESDAY, Aug. 16, 2023 – All infants should receive the new long-acting preventive monoclonal antibody for respiratory syncytial virus (RSV), the nation’s leading pediatrics group said. The A...
Monthly News Roundup - July 2023
FDA Clears Opill, the First Over-the-Counter (OTC) Oral Birth Control Pill History in women’s health was made in July when the FDA cleared Opill (norgestrel 0.075 mg), the first over-the-counter (...
FDA Approves Beyfortus (nirsevimab) for the Prevention of RSV Lower Respiratory Tract Disease in Infants
July 17, 2023 – AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns ...
Ask a question
To post your own question to this support group, sign in or create an account.